Use of a meningococcal group B vaccine (4CMenB) in populations at high risk of gonorrhoea in the UK
SN Ladhani, PJ White, H Campbell… - The Lancet Infectious …, 2024 - thelancet.com
The meningococcal group B vaccine, 4CMenB, is a broad-spectrum, recombinant protein
vaccine that is licensed for protection against meningococcal group B disease in children …
vaccine that is licensed for protection against meningococcal group B disease in children …
Range of invasive meningococcal disease sequelae and health economic application–a systematic and clinical review
Background Invasive meningococcal disease (IMD) is uncommon, life-threatening, with
many diverse sequelae. The aims were to: 1) comprehensively characterise the sequelae; 2) …
many diverse sequelae. The aims were to: 1) comprehensively characterise the sequelae; 2) …
Looking beyond meningococcal B with the 4CMenB vaccine: the Neisseria effect
Infections with Neisseria meningitidis and Neisseria gonorrhoeae have different clinical
manifestations, but the bacteria share up to 80–90% genome sequence identity. The …
manifestations, but the bacteria share up to 80–90% genome sequence identity. The …
Effectiveness of Meningococcal Vaccines at Reducing Invasive Meningococcal Disease and Pharyngeal Neisseria meningitidis Carriage: A Systematic Review and …
M McMillan, A Chandrakumar… - Clinical Infectious …, 2021 - academic.oup.com
Background Invasive meningococcal disease (IMD), caused by Neisseria meningitidis,
leads to significant morbidity and mortality worldwide. This review aimed to establish the …
leads to significant morbidity and mortality worldwide. This review aimed to establish the …
Equity in vaccination policies to overcome social deprivation as a risk factor for invasive meningococcal disease
Introduction Social deprivation is associated with poorer healthcare access. Vaccination is
among the most effective public health interventions and achieving equity in vaccination …
among the most effective public health interventions and achieving equity in vaccination …
[HTML][HTML] Recent advances in meningococcal B disease prevention: real-world evidence from 4CMenB vaccination
F Martinón-Torres, A Banzhoff, C Azzari, P De Wals… - Journal of Infection, 2021 - Elsevier
Objectives 4CMenB is a broadly protective vaccine against invasive meningococcal
capsular group B disease (MenB IMD). Licensed worldwide based on immunogenicity and …
capsular group B disease (MenB IMD). Licensed worldwide based on immunogenicity and …
4CMenB journey to the 10-year anniversary and beyond
The 4-component meningococcal serogroup B (MenB) vaccine, 4CMenB, the first broadly
protective, protein-based MenB vaccine to be licensed, is now registered in more than 50 …
protective, protein-based MenB vaccine to be licensed, is now registered in more than 50 …
[HTML][HTML] Meningococcal disease in North America: updates from the global meningococcal initiative
EJ Asturias, X Bai, JA Bettinger, R Borrow, DN Castillo… - Journal of Infection, 2022 - Elsevier
This review summarizes the recent Global Meningococcal Initiative (GMI) regional meeting,
which explored meningococcal disease in North America. Invasive meningococcal disease …
which explored meningococcal disease in North America. Invasive meningococcal disease …
Evolving strategies for meningococcal vaccination in Europe: overview and key determinants for current and future considerations
Invasive meningococcal disease (IMD) is a life-threatening, unpredictable condition.
Vaccines are available against 5 of the 6 meningococcal serogroups (Men) accounting for …
Vaccines are available against 5 of the 6 meningococcal serogroups (Men) accounting for …
Immunogenicity and protective capacity of a CpG ODN adjuvanted alum adsorbed bivalent meningococcal outer membrane vesicle vaccine
Invasive meningococcal disease (IMD) is caused by Neisseria meningitidis, with the main
serogroups responsible for the disease being A, B, C, W, X, and Y. To date, several vaccines …
serogroups responsible for the disease being A, B, C, W, X, and Y. To date, several vaccines …